Bon Secours Nears $6B Surgery Partners Takeover at $20 a Share: FT

The Quick Take

• Bon Secours Mercy Health is in late-stage talks to acquire a majority stake in Surgery Partners
• The deal values Surgery Partners at approximately $20 per share, implying a roughly $6 billion valuation
• Surgery Partners operates outpatient surgery centers, a sector seeing rapid consolidation by healthcare systems

Bon Secours Mercy Health's near-$6 billion bid for Surgery Partners represents one of the largest US healthcare acquisitions of 2026, reflecting an accelerating consolidation trend in outpatient surgical services. Not-for-profit health systems have been expanding their ambulatory surgery center portfolios as patient volume shifts from inpatient hospitals to lower-cost outpatient settings — a structural secular change that compresses traditional hospital margins while creating scale advantages for large integrated systems. Bon Secours's move signals strategic intent to own the full care continuum from acute inpatient to ambulatory outpatient.

A transaction at $20 per share would represent a significant premium to where Surgery Partners (SGRY) had been trading amid profitability challenges in the outpatient segment, and would likely trigger comparable-company re-ratings for peers including Surgical Care Affiliates, USPI (a Tenet Healthcare subsidiary), and AmSurg. Private equity-backed ambulatory surgery portfolios held by KKR and TPG could see valuation uplift if the deal establishes a new benchmark multiple for the sector. Hospital stocks such as HCA Healthcare and Community Health Systems face increased competitive pressure from better-capitalized integrated systems.

Investors should watch for: formal deal announcement with final pricing, any regulatory scrutiny under FTC's healthcare merger review framework, and financing terms for Bon Secours — as a not-for-profit, it may use bond issuance that creates public debt market monitoring triggers. The macro variable is whether the FTC's healthcare M&A posture hardens as the Biden-era antitrust framework transitions, which could create deal-completion risk for this and other pending healthcare consolidations. Post-announcement, Surgery Partners' peers will be the most immediate trading catalyst.

Synthesized from 1 source.